Is Pharma Mar SA halal to invest in?

As of August 2026, Pharma Mar SA PHM.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Pharma Mar SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Pharma Mar SA using these criteria to determine its compliance status.

Can Muslims buy shares of Pharma Mar SA?

Muslim investors may consider investing in Pharma Mar SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Pharma Mar SA classified as HALAL?

Musaffa determines the Shariah status of Pharma Mar SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Pharma Mar SA updated?

The Shariah compliance status of Pharma Mar SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Pharma Mar SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Pharma Mar SA?

You can check the latest Shariah compliance status of Pharma Mar SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Pharma Mar SA PHM.VI

Last Updated: Aug 07, 12:00 AM·WBAG

PHM.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Pharma Mar SA is classified as halal.

HALAL

Report Source: undefined Quarter Report

Pharma Mar SA. Stock Analysis PHM.VI

Austria Health Care Small Cap

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company employs 505 full-time employees The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.